JP6496301B2 - Ｒａｓ／ｒａｆ／ｍｅｋ／ｅｒｋ経路およびｐｉ３ｋ／ａｋｔ／ｐｔｅｎ／ｍｔｏｒ経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン - Google Patents

Ｒａｓ／ｒａｆ／ｍｅｋ／ｅｒｋ経路およびｐｉ３ｋ／ａｋｔ／ｐｔｅｎ／ｍｔｏｒ経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン Download PDF

Info

Publication number
JP6496301B2
JP6496301B2 JP2016507671A JP2016507671A JP6496301B2 JP 6496301 B2 JP6496301 B2 JP 6496301B2 JP 2016507671 A JP2016507671 A JP 2016507671A JP 2016507671 A JP2016507671 A JP 2016507671A JP 6496301 B2 JP6496301 B2 JP 6496301B2
Authority
JP
Japan
Prior art keywords
sulfonamide
fluorophenyl
fluoropropane
methoxy
morpholinoquinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016507671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519685A (ja
JP2016519685A5 (enExample
Inventor
トンプソン，スコット・ケイ
スミス，ロジャー・エイ
レディ，サンジーヴァ
ジョン，タイラー・エム
ニャバナンディ，ヴィジェイ・クマール
サブラーマンヤ，ホサハリ
ポトルリ，ヴィジェイ
パニグラヒ，スニル・クマール
ナディパリ，プラバカーラ・ラオ
セングプタ，サウミトラ
Original Assignee
アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー filed Critical アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー
Publication of JP2016519685A publication Critical patent/JP2016519685A/ja
Publication of JP2016519685A5 publication Critical patent/JP2016519685A5/ja
Application granted granted Critical
Publication of JP6496301B2 publication Critical patent/JP6496301B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016507671A 2013-04-12 2014-04-11 Ｒａｓ／ｒａｆ／ｍｅｋ／ｅｒｋ経路およびｐｉ３ｋ／ａｋｔ／ｐｔｅｎ／ｍｔｏｒ経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン Expired - Fee Related JP6496301B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811408P 2013-04-12 2013-04-12
US61/811,408 2013-04-12
PCT/US2014/033727 WO2014169167A1 (en) 2013-04-12 2014-04-11 Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways

Publications (3)

Publication Number Publication Date
JP2016519685A JP2016519685A (ja) 2016-07-07
JP2016519685A5 JP2016519685A5 (enExample) 2017-06-01
JP6496301B2 true JP6496301B2 (ja) 2019-04-03

Family

ID=50771612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507671A Expired - Fee Related JP6496301B2 (ja) 2013-04-12 2014-04-11 Ｒａｓ／ｒａｆ／ｍｅｋ／ｅｒｋ経路およびｐｉ３ｋ／ａｋｔ／ｐｔｅｎ／ｍｔｏｒ経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン

Country Status (13)

Country Link
US (5) US9499495B2 (enExample)
EP (1) EP2984088B1 (enExample)
JP (1) JP6496301B2 (enExample)
KR (1) KR20150143672A (enExample)
CN (1) CN105283454B (enExample)
AU (1) AU2014250836C1 (enExample)
BR (1) BR112015025901A8 (enExample)
CA (1) CA2909310A1 (enExample)
IL (2) IL242020B (enExample)
MX (1) MX2015014387A (enExample)
RU (1) RU2015148359A (enExample)
WO (1) WO2014169167A1 (enExample)
ZA (1) ZA201507750B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
JP2019519593A (ja) * 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
CN108239075B (zh) * 2016-12-26 2021-07-02 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239074B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CA3048546A1 (en) * 2016-12-26 2018-07-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
CN108239076B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
WO2018212774A1 (en) * 2017-05-17 2018-11-22 Vanderbilt University Quinazoline compounds as modulators of ras signaling
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US10695296B2 (en) * 2017-07-14 2020-06-30 Asana Biosciences, Llc Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredient
CN108623582A (zh) * 2017-10-10 2018-10-09 河南省锐达医药科技有限公司 一类新型含取代基吡啶并嘧啶化合物的制备方法
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
CN111499634B (zh) * 2019-01-31 2023-05-12 贝达药业股份有限公司 一种喹唑啉化合物及其在医药上的应用
CN112341434B (zh) * 2019-08-08 2021-11-26 恩瑞生物医药科技（上海）有限公司 PI3K/mTOR蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
HUE067805T2 (hu) 2019-11-01 2024-11-28 Fmc Corp Hatékony új eljárás 2-amino-5-klór-N,3-dimetilbenzamid elõállítására
CN115894606A (zh) 2019-11-04 2023-04-04 锐新医药公司 Ras抑制剂
KR20230067635A (ko) 2020-09-15 2023-05-16 레볼루션 메디슨즈, 인크. 암의 치료에서 ras 억제제로서 인돌 유도체
JP2023549540A (ja) * 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
CN118852330A (zh) 2021-05-05 2024-10-29 锐新医药公司 用于治疗癌症的ras抑制剂
CN113416181B (zh) * 2021-08-02 2022-05-03 四川大学 喹唑啉类衍生物及其用途
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023131122A1 (zh) * 2022-01-04 2023-07-13 劲方医药科技(上海)有限公司 稠环取代的六元杂环化合物及其制法和用途
CN115894211A (zh) * 2022-11-10 2023-04-04 山东龙立恒医药有限公司 一种3-羟基-4-甲基苯甲酸的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
TW200801012A (en) * 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
WO2009108637A1 (en) * 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
EP2531498B1 (en) * 2010-02-05 2016-07-13 Novartis AG Compounds and compositions as protein kinase inhibitors
EP2539337A1 (en) * 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors

Also Published As

Publication number Publication date
IL242020B (en) 2019-08-29
RU2015148359A (ru) 2017-05-15
US10226468B2 (en) 2019-03-12
KR20150143672A (ko) 2015-12-23
US20190151327A1 (en) 2019-05-23
US20160068496A1 (en) 2016-03-10
AU2014250836B2 (en) 2018-07-12
EP2984088A1 (en) 2016-02-17
MX2015014387A (es) 2017-04-10
CN105283454B (zh) 2019-10-29
AU2014250836A1 (en) 2015-11-26
HK1215810A1 (en) 2016-09-15
AU2014250836C1 (en) 2019-01-17
US20170027953A1 (en) 2017-02-02
US9499495B2 (en) 2016-11-22
CA2909310A1 (en) 2014-10-16
CN105283454A (zh) 2016-01-27
US10912779B2 (en) 2021-02-09
US9757382B2 (en) 2017-09-12
WO2014169167A1 (en) 2014-10-16
JP2016519685A (ja) 2016-07-07
IL262314A (en) 2018-11-29
BR112015025901A8 (pt) 2020-01-14
US20210113578A1 (en) 2021-04-22
EP2984088B1 (en) 2019-03-20
BR112015025901A2 (pt) 2017-07-25
ZA201507750B (en) 2017-08-30
US20170290838A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
JP6496301B2 (ja) Ｒａｓ／ｒａｆ／ｍｅｋ／ｅｒｋ経路およびｐｉ３ｋ／ａｋｔ／ｐｔｅｎ／ｍｔｏｒ経路の二重阻害剤としてのキナゾリンおよびアザキナゾリン
US9334267B2 (en) RAF inhibitor compounds
JP6035423B2 (ja) 新規な縮合ピリミジン化合物又はその塩
EA024162B1 (ru) Производные хинолина в качестве ингибиторов киназы
WO2015038417A1 (en) Compounds for regulating fak and/or src pathways
US9145411B2 (en) Substituted amino-pyrimidine derivatives
US9388165B2 (en) Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase
AU2015276699B2 (en) Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor
US12404249B2 (en) Heterocyclic derivatives and use thereof
KR20230004612A (ko) 염증성 질병의 치료를 위한 치환된 피리딘
US20220289719A1 (en) Heterocyclic compounds as mnk inhibitors
WO2012058671A1 (en) Substituted quinazoline and pyrido-pyrimidine derivatives
US20230348399A1 (en) Novel pyrimidine derivative and use thereof
KR102572704B1 (ko) 신규한 피리미딘 유도체 및 이의 용도
CN113004282B (zh) 取代的炔基杂环化合物
WO2015014283A1 (zh) 蛋白酪氨酸激酶抑制剂及其应用
HK1215810B (en) Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
US20200079773A1 (en) Carboxylic acid derivatives of pyridoquinazolines useful as protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170410

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190308

R150 Certificate of patent or registration of utility model

Ref document number: 6496301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees